Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1980;62:449-461

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Circulation, Vol 62, 449-461, Copyright © 1980 by American Heart Association


ARTICLES

Persantine and aspirin in coronary heart disease. The Persantine- Aspirin Reinfarction Study Research Group


In the Persantine-Aspirin Reinfarction Study (PARIS) trial, 2026 persons who had recovered from myocardial infarction (MI) were randomized into three groups: Persantine plus aspirin (PR/A) (n = 810); aspirin alone (ASA) (n = 810); placebo (PLBO) (n = 406). The average length of follow-up study was 41 months. Results for the three specified primary end points were: total mortality 16% lower in PR/A and 18% lower in ASA compared with PLBO; coronary mortality 24% and 21% lower; incidence of nonfatal MI plus fatal coronary disease 25% and 24% lower. These differences were not satistically significant by the study criterion (Z greater than or equal to 2.6). By life-table analysis, the rates of coronary mortality and coronary incidence were about 50% lower in the PR/A group than in the PLBO group from 8-24 months, and for coronary incidence all Z values were greater than or equal to 2.6; ASA rates were about 30% lower than PLBO rates, and for coronary incidence, Z values were greater than or equal to 2.6 at two points. For these end points, from 8-20 months, PR/A rates were about 30% lower than ASA rates, but all Z values were less than 2.0 PR/A and ASA patients entering within 6 months of last MI showed the largest percentage reductions in mortality; only the difference between PR/A and PLBO groups for 3-year coronary mortality yielded a Z value of 2.6.


This article has been cited by other articles:


Home page
Med Care Res RevHome page
T. A. Nahra, K. L. Reiter, R. A. Hirth, J. E. Shermer, and J. R. C. Wheeler
Cost-Effectiveness of Hospital Pay-for-Performance Incentives
Med Care Res Rev, February 1, 2006; 63(1_suppl): 49S - 72S.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
H. M. Krumholz, Y.-T. Chen, and M. J. Radford
Aspirin and the Treatment of Heart Failure in the Elderly
Arch Intern Med, February 26, 2001; 161(4): 577 - 582.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade
Antithrombotic Agents in Coronary Artery Disease
Chest, January 1, 2001; 119(1_suppl): 228S - 252S.
[Full Text] [PDF]


Home page
NeurologyHome page
G. W. Albers
Choice of endpoints in antiplatelet trials: Which outcomes are most relevant to stroke patients?
Neurology, March 14, 2000; 54(5): 1022 - 1028.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. H. Awtry and J. Loscalzo
Aspirin
Circulation, March 14, 2000; 101(10): 1206 - 1218.
[Full Text] [PDF]


Home page
Arch NeurolHome page
R. G. Hart, J. L. Halperin, R. McBride, O. Benavente, M. Man-Son-Hing, and R. A. Kronmal
Aspirin for the Primary Prevention of Stroke and Other Major Vascular Events: Meta-analysis and Hypotheses
Arch Neurol, March 1, 2000; 57(3): 326 - 332.
[Abstract] [Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
A. Nabuchi, Q. H. Li, and Z. L. Zhu
Total Occlusion of Left Main Coronary Artery Trunk in a Young Man
Asian Cardiovasc Thorac Ann, December 1, 1999; 7(4): 313 - 315.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
V. M. Figueredo, I. Diamond, H.-Z. Zhou, and S. A. Camacho
Chronic dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury
Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H2091 - H2097.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. L. Wilterdink and J. D. Easton
Dipyridamole Plus Aspirin in Cerebrovascular Disease
Arch Neurol, September 1, 1999; 56(9): 1087 - 1092.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. B. Gorelick, G. V. R. Born, R. B. D'Agostino, D. F. Hanley Jr, L. Moye, and C. J. Pepine
Therapeutic Benefit : Aspirin Revisited in Light of the Introduction of Clopidogrel
Stroke, August 1, 1999; 30(8): 1716 - 1721.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. He, P. K. Whelton, B. Vu, and M. J. Klag
Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials
JAMA, December 9, 1998; 280(22): 1930 - 1935.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care
BMJ, April 25, 1998; 316(7140): 1303 - 1309.
[Full Text]


Home page
NEJMHome page
E. J. Weiss, P. F. Bray, M. Tayback, S. P. Schulman, T. S. Kickler, L. C. Becker, J. L. Weiss, G. Gerstenblith, and P. J. Goldschmidt-Clermont
A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis
N. Engl. J. Med., April 25, 1996; 334(17): 1090 - 1094.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
J. Weil, D. Colin-Jones, M. Langman, D. Lawson, R. Logan, M. Murphy, M. Rawlins, M. Vessey, and P. Wainwright
Prophylactic aspirin and risk of peptic ulcer bleeding
BMJ, April 1, 1995; 310(6983): 827 - 830.
[Abstract] [Full Text]


Home page
Med Decis MakingHome page
V. Hasselblad and D. C. McCrory
Meta-analytic Tools for Medical Decision Making: A Practical Guide
Med Decis Making, February 1, 1995; 15(1): 81 - 96.
[Abstract] [PDF]


Home page
NEJMHome page
C. Patrono
Aspirin as an Antiplatelet Drug
N. Engl. J. Med., May 5, 1994; 330(18): 1287 - 1294.
[Full Text]


Home page
BMJHome page
Antiplatelet Trialists
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
BMJ, January 8, 1994; 308(6921): 81 - 106.
[Abstract] [Full Text]